Triple negative breast cancer: Therapeutic and prognostic implications

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 8, 2011, Pages 2139-2143

  Brady West, Doreen C ^a   McGrowder, Donovan A ^a  

^a UNIVERSITY OF THE WEST INDIES   (Jamaica)

Author keywords

Chemotherapy; Epidemiology; Prognosis; Targeted agents; Triple negative breast cancer

Indexed keywords

EID: 84858144705     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Note

References (37)

1. Baselga J, Gomez P, Awada A, et al. (2010). The addition of cetuximab to cisplatin increases overall response rate (ORR) and progression-free survival (PFS) in metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II study (BALI-1). Ann Oncol, 21, 96-121.
2. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007). Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the socalled triple-negative phenotype-a population-based study from the California Cancer Registry. Cancer, 109, 1721-8.
3. Böcker W, Bier B, Freytag G, et al. (1992). An immunohistochemical study of the breast using antibodies to basal and luminal keratins, alpha-smooth muscle actin, vimentin, collagen IV. Virchows Arch A Pathol Anat Histopathol, 421, 315-22.
4. Burgess AW (2008). EGFR family: structure physiology signaling and therapeutic targets. Growth Factors, 26, 263-74.
5. Byrski T, Huzarski T, Dent R, et al. (2009). Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat, 115, 359-63.
6. Carey LA, Dees EC, Sawyer L, et al. (2007). The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res, 13, 2329-34.
7. Carey L, Perou C, Livasy C, et al. (2006). Race, breast cancer subtypes and survival in the Carolina breast cancer study. JAMA, 295, 2492-502.
8. Dent R, Trudeau M, Pritchard KI, et al. (2007). Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res, 13, 4429-34.
9. Chan A, Miles DW, Pivot X (2010). Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer. Ann Oncol, 21, 2305-15.
10. Cheang MC, Voduc D, Bajdik C, et al. (2008). Basal-like breast cancer defined by five biomarkers has superior prognostic value than triplenegative phenotype. Clin Cancer Res, 14, 368-76.
11. Collins LC, Martyniak A, Kandel MJ et al. (2009). Basal Cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers. Am J Surg Pathol, 33, 1093-97.
12. Dolle JM, Daling JR, White E et al. (2009). Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomarkers Prev, 18, 1157-66.
13. Foulkes WD, Smith IE, Rheis-Filho JS (2010). Triple-negative breast cancer. N Engl J Med, 363, 1938-48.
14. Guarneri V, Broglio K, Kau SW et al. (2006). Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol, 24, 1037-44.
15. Haffty BG, Yang QF, Reiss M et al. (2006). Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol, 24, 5652-7.
16. Harris LN, Broadwater G, Lin NU, et al. (2006). Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res, 8, R66.
17. Heitz F, Harter P, Lueck HJ, et al. (2009). Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. Eur J Cancer, 45, 2792-8.
18. Kreike B, van Kouwenhove M, Horlings H, et al. (2007). Gene expression profiling and histopathological characterization of triple-negative/ basal-like breast carcinomas. Breast Cancer Res, 9, R65.
19. Liedtke C, Mazouni C, Hess KR, et al. (2008). Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol, 26, 1275-81.
20. Lin NU, Vanderplas A, Hughes ME, et al. (2009). Clinicopathological features and sites of recurrence according to breast cancer subtype in the National Comprehensive Cancer Network (NCCN). ASCO Meeting Abstracts, 27, 543.
21. Livasy CA, Karaca G, Nanda R, et al. (2006). Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol, 19, 264-71.
22. Meche A, Cimpean AM, Raica M. (2009). Immunohistochemical expression and significance of epidermal growth factor receptor (EGFR) in breast cancer. Rom J Morphol Embryol, 50, 217-21.
23. Millikan RC, Newman B, Tse CK, et al. (2008). Epidemiology of basal-like breast cancer. Breast Cancer Res Treat, 109, 123-39.
24. Morris GJ, Naidu S, Topham AK, et al. (2007). Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients-a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer, 110, 876-84.
25. Niwinska A, Murawska M, Pogoda K (2010). Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Ann Oncol, 21, 942-8.
26. O'Shaughnessy J, Dieras V, Glaspy J, et al. (2009). Comparison of Subgroup Analyses of PFS from Three Phase III Studies of Bevacizumab in Combination with Chemotherapy in Patients with HER2-Negative Metastatic Breast Cancer (MBC). Cancer Res, 69, 207.
27. O'Shaughnessy J, Osborne C, Pippen JE, et al. (2011). Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med, 364, 205-14.
28. Perou CM, Sorlie T, Eisen MB, et al. (2000). Molecular portraits of human breast tumours. Nature, 406, 747-52.
29. Rakha EA, El-Sayed ME, Green AR, et al. (2007). Prognostic markers in triple-negative breast cancer. Cancer, 109, 25-32.
30. Robert NJ, Dieras V, Glaspy J, et al. (2009). RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC)[abstract 1005]. J Clin Oncol, 27, 1005.
31. Rottenberg S, Jaspers JE, Kersbergen A, et al. (2008). High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA, 105, 17079-84.
32. Shaheenah D (2010). Triple-Negative Breast Cancer: Epidemiology and management options. Drugs, 70, 2247-58.
33. Silver DP, Richardson AL, Eklund AC, et al. (2010). Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol, 28, 1145-53.
34. Sirohi B, Arnedos M, Popat S, et al. (2008). Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol, 19, 1847-52.
35. Siziopikou KP, Ariga R, Proussaloglou KE, et al. (2006). The challenging estrogen receptor-negative/progesterone receptor-negative/HER-2-negative patient: a promising candidate for epidermal growth factor receptor-targeted therapy? Breast J, 12, 360-2.
36. Smid M, Wang Y, Zhang Y, et al. (2008). Subtypes of breast cancer show preferential site of relapse. Cancer Res, 68, 3108-14.
37. Viale G, Rotmensz N, Maisonneuve P, et al. (2009). Invasive ductal carcinoma of the breast with the triple-negative phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat, 116, 317-28.